Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Fortrea.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
101actual
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-11 | actual | When the study began enrolling |
| Primary completion | 2026-02-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-24 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mild Asthma
Interventions
- Combination product: Albuterol/Budesonide — also filed as AIRSUPRA, BDA MDI HFA
- Combination product: Albuterol — also filed as AS MDI
Primary outcome
what the primary-completion date above is the date OFChange from baseline to maximum value of daily morning FeNO
measured Daily over 12 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed